BR112013026883A2 - Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica - Google Patents

Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica

Info

Publication number
BR112013026883A2
BR112013026883A2 BR112013026883A BR112013026883A BR112013026883A2 BR 112013026883 A2 BR112013026883 A2 BR 112013026883A2 BR 112013026883 A BR112013026883 A BR 112013026883A BR 112013026883 A BR112013026883 A BR 112013026883A BR 112013026883 A2 BR112013026883 A2 BR 112013026883A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition
kit
producing
tnfr
Prior art date
Application number
BR112013026883A
Other languages
English (en)
Inventor
Britta Deutel
Sabine Fuertinger
Thomas Lauber
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR112013026883A2 publication Critical patent/BR112013026883A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica a presente invenção refere-se a formulações farmacêuticas líquidas estáveis da proteína de fusão tnfr:fc que compreendem diferentes sistemas tampão e estabilizantes. em particular, poderia ser demonstrado que a estabilidade física da tnfr:fc é significativamente melhorada pelo uso de um sistema tampão de citrato e lisina com estabilizante.
BR112013026883A 2011-04-20 2012-04-19 Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica BR112013026883A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163171 2011-04-20
PCT/EP2012/057119 WO2012143418A1 (en) 2011-04-20 2012-04-19 STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Publications (1)

Publication Number Publication Date
BR112013026883A2 true BR112013026883A2 (pt) 2021-12-07

Family

ID=44454066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026883A BR112013026883A2 (pt) 2011-04-20 2012-04-19 Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica

Country Status (10)

Country Link
US (1) US9453067B2 (pt)
EP (1) EP2699265B1 (pt)
JP (1) JP5996631B2 (pt)
KR (1) KR101673654B1 (pt)
AU (1) AU2012244764B2 (pt)
BR (1) BR112013026883A2 (pt)
CA (1) CA2833427C (pt)
ES (1) ES2759931T3 (pt)
RU (1) RU2614257C2 (pt)
WO (1) WO2012143418A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
US8498695B2 (en) 2006-12-22 2013-07-30 Novadaq Technologies Inc. Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013059410A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
RS60226B1 (sr) 2012-09-07 2020-06-30 Coherus Biosciences Inc Stabilne vodene formulacije adalimumaba
EP2895188B1 (en) 2012-09-11 2017-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
PL2919801T3 (pl) * 2012-10-26 2021-01-25 Lupin Atlantis Holdings, Sa Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
KR101419884B1 (ko) * 2012-11-27 2014-07-16 (주)알테오젠 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
JP2014214153A (ja) * 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
BR112015027764A2 (pt) * 2013-05-02 2017-08-29 Mabxience S A Formulações alternativas para os polipeptídeos de fusão de tnfr: fc
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CA2930227C (en) * 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
EP3236990B1 (en) * 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CA2998920A1 (en) 2015-11-13 2017-05-18 Novadaq Technologies ULC Systems and methods for illumination and imaging of a target
EP3394095B1 (en) * 2015-12-23 2023-09-27 Phoenix Tissue Repair Inc. Collagen 7 compositions and methods of using the same
EP4155716A1 (en) 2016-01-26 2023-03-29 Stryker European Operations Limited Image sensor assembly
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US10869645B2 (en) 2016-06-14 2020-12-22 Stryker European Operations Limited Methods and systems for adaptive imaging for low light signal enhancement in medical visualization
CA3036965A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A method for stabilization of a biopharmaceutical drug product during processing
JP6884858B2 (ja) * 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP3533441A4 (en) 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
CA3043487A1 (en) * 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
EP3580609B1 (en) 2017-02-10 2023-05-24 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
WO2018200533A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
EP3816263A4 (en) * 2018-08-31 2022-03-09 CJ Cheiljedang Corporation METHOD FOR INHIBITING DUST GENERATION, SOIL STABILIZER COMPOSITION AND SPRAYING DEVICE CONTAINING THEREOF
KR102284844B1 (ko) 2018-08-31 2021-08-03 씨제이제일제당 주식회사 먼지 생성을 억제하는 방법, 토양안정제 조성물, 및 이를 포함하는 분무 장치
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN111103432B (zh) * 2020-01-07 2022-05-03 郑州安图生物工程股份有限公司 一种促甲状腺激素受体的冻干辅助制剂及冻干方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
JP4583762B2 (ja) * 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
RU2006101216A (ru) * 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
AU2004319758A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
AU2006244014B2 (en) * 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN102946858B (zh) 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂

Also Published As

Publication number Publication date
CA2833427C (en) 2019-09-24
JP5996631B2 (ja) 2016-09-21
AU2012244764A1 (en) 2013-10-31
AU2012244764B2 (en) 2016-10-13
EP2699265A1 (en) 2014-02-26
JP2014519484A (ja) 2014-08-14
US9453067B2 (en) 2016-09-27
KR101673654B1 (ko) 2016-11-07
CA2833427A1 (en) 2012-10-26
RU2614257C2 (ru) 2017-03-24
ES2759931T3 (es) 2020-05-12
US20140186351A1 (en) 2014-07-03
RU2013151303A (ru) 2015-05-27
KR20140027274A (ko) 2014-03-06
EP2699265B1 (en) 2019-10-16
WO2012143418A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
BR112015022119A2 (pt) Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
ECSP13012384A (es) Composición acuosa que contiene bromhexina
BR112016001114A2 (pt) membros da família tnf direcionados modificados
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
EA201590518A1 (ru) Стабильные водные составы адалимумаба
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
BR112015022210A8 (pt) formulações de anticorpo
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112015010948A2 (pt) meios de cultura de células
BR112015008912A2 (pt) composições solidificáveis compreendendo volastonita e pedra-pomes e métodos de uso
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
IN2015DN03322A (pt)
BR112013009083A2 (pt) anticorpos humanos de oncostatin m e métodos de uso
ECSP15002095A (es) Formulación farmacéutica
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
MX2014014318A (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2719 DE 14/02/2023.